文献速递淋巴瘤

原发肠道结外鼻型NK/T细胞淋巴瘤临床特征与生存分析

[Clinical characteristics and survival analysis of primary intestinal extranodal NK/T-cell lymphoma, nasal type].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2020-01-01

该回顾性研究纳入34例原发肠道ENKTL患者,占肠道淋巴瘤的16.2%,以青中年男性为主,腹痛最常见,多伴B症状和LDH升高;中位生存仅60天,ECOG评分、血清LDH、IPI评分及并发症与总生存率显著相关。

要点

  • 原发肠道ENKTL占肠道淋巴瘤16.2%,多见于青中年男性,腹痛最常见。
  • 中位生存时间仅60天,ECOG评分、LDH、IPI评分及并发症影响OS。
  • IPI低危且无并发症者总生存率较高。

核心结论

  • 原发肠道ENKTL多见于青中年男性,以腹痛、B症状及LDH升高为常见表现,病变多位于大肠,混合型及溃疡型为主。
  • IPI评分低危且无并发症者总生存率较高。

研究设计与样本

  • 回顾性分析2009年1月至2019年12月空军军医大学第一附属医院肠道淋巴瘤病例,筛选出原发肠道ENKTL 34例。
  • 评估一般情况、症状、ECOG评分、血清LDH及β2微球蛋白、病变部位与形态、结外侵犯数目、Lugano分期、病理特征及生存结局。

主要发现

  • 原发肠道ENKTL占肠道淋巴瘤16.2%(34/210),男26例、女8例,中位年龄45岁(范围20-69岁),≤60岁者占85.3%。
  • 症状包括腹痛76.5%、腹泻20.6%、便血29.4%、腹部包块2.9%,85.3%伴B症状,73.5%血清LDH升高。
  • 病变部位为大肠52.9%、小肠29.4%、两者均受累17.7%;内镜分型为隆起型8.8%、溃疡型32.4%、弥漫型2.9%、混合型55.9%。
  • Lugano分期Ⅰ/Ⅱ期70.6%(24例)、Ⅳ期29.4%(10例);EBER阳性94.1%;中位生存时间60天。
  • ECOG评分、血清LDH、IPI评分及并发症与总生存率差异显著(P值分别为0.037、0.009、0.002和0.000)。

临床怎么用

  • 对原发肠道ENKTL患者应关注ECOG评分、血清LDH、IPI评分及并发症,用于预后分层。
  • IPI低危且无并发症者可能获得更长生存时间。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To retrospectively analyze the clinical features and survival analysis of primary intestinal extranodal NK/T-cell lymphoma nasal type(ENKTL). Methods: Patients with intestinal lymphoma at the First Affiliated Hospital of Air Force Military Medical University were collected from January 2009 to December 2019, and those with primary intestinal ENKTL screened. The general situation, main symptoms, ECOG scale, lactic dehydrogenase(LDH), and β(2)-microglobulin(β(2)-MG)in the serum, lesion site and form, numbers of extranodal invasion, Lugano stage, pathological features, and lifetime and survival outcomes were evaluated. Results: In total, 34 patients with confirmed diagnosis of primary intestinal ENKTL were identified. The incidence rate of primary intestinal ENKTL is 16.2% (34/210). A total of 26 patients were men and 8 were women with the median age at diagnosis of 45 (range, 20-69)years and patients younger than 60 years account for 85.3%. It included abdominal pain (76.5%), diarrhea(20.6%), hematochezia(29.4%), and abdominal mass(2.9%), 85.3% with B-symptoms, and abnormally elevated LDH in the serum(73.5%). The lesion sites included large intestine(52.9%), small intestine(29.4%), and both of them(17.7%). The lesion forms were featured by mass(8.8%), ulcer(32.4%), diffuse infiltration(2.9%), and hybrid(55.9%). Lugano stage included stage Ⅰ/Ⅱ (70.6%)24 patients and stage Ⅳ(29.4%)10 patients. About 94.1% patients were EBER positive. The median survival time was 60 days. The overall survival rate had significant differences on ECOG scale, LDH in the serum, IPI score and complications(P=0.037, 0.009, 0.002, and 0.000, respectively). Conclusion: Primary intestinal ENKTL was commonly observed in men at young or middle age, and the most common symptom was abdominal pain, often with B-symptoms, abnormally elevated LDH in the serum. The most common site was the large intestine. The lesion forms were mainly featured by the hybrid and ulcer. It seemed that patients with IPI low-risk group and without any complication would have longer survival time. 目的: 回顾性研究原发肠道结外鼻型NK/T细胞淋巴瘤(ENKTL)患者的临床特征、生存及影响预后的因素。 方法: 收集2009年1月至2019年12月就诊于空军军医大学第一附属医院诊断为肠道淋巴瘤的病例,从中筛选原发肠道ENKTL并收集患者资料进行回顾性分析。 结果: 在210例肠道淋巴瘤患者中,原发肠道ENKTL患者34例(16.2%),其中男26例,女8例,中位年龄45(20~69)岁,年龄≤60岁者占85.3%。主要症状:腹痛(76.5%)、腹泻(20.6%)、便血(29.4%)、腹部包块(2.9%),85.3%伴B症状,73.5%血清LDH升高。病变部位:大肠(52.9%)、小肠(29.4%)、大肠及小肠均受累(17.7%)。内镜分型:隆起型(8.8%)、溃疡型(32.4%)、弥漫型(2.9%)和混合型(55.9%)。Lugano分期Ⅰ/Ⅱ期24例(70.6%),Ⅳ期10例(29.4%)。组织病理免疫组化EBER阳性者占94.1%。中位生存时间为60 d。ECOG评分、血清LDH、IPI评分及是否有并发症影响患者的OS率(P值分别为0.037、0.009、0.002和0.000)。 结论: 原发肠道ENKTL多见于青中年男性,以腹痛最多见,常合并B症状,血清LDH多异常升高,病变多位于大肠,病灶主要呈混合型或溃疡型。IPI评分低危、无并发症者OS率较高。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Li Y, Wang XJ, Li YN, et al. [Clinical characteristics and survival analysis of primary intestinal extranodal NK/T-cell lymphoma, nasal type]. Zhonghua Xue Ye Xue Za Zhi. 2020. PMID: 33190438. doi:10.3760/cma.j.issn.0253-2727.2020.10.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。